CRISPR Therapeutics AG (CRSP) concluded trading on Wednesday at a closing price of $60.08, with 5.31 million shares of worth about $318.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 46.47% during that period and on July 09, 2025 the price saw a gain of about 9.60%. Currently the company’s common shares owned by public are about 86.36M shares, out of which, 82.79M shares are available for trading.
Stock saw a price change of 23.85% in past 5 days and over the past one month there was a price change of 43.53%. Year-to-date (YTD), CRSP shares are showing a performance of 13.15% which increased to 52.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $30.04 but also hit the highest price of $63.68 during that period. The average intraday trading volume for CRISPR Therapeutics AG shares is 2.61 million. The stock is currently trading 27.58% above its 20-day simple moving average (SMA20), while that difference is up 45.35% for SMA50 and it goes to 38.73% higher than SMA200.
CRISPR Therapeutics AG (NASDAQ: CRSP) currently have 86.36M outstanding shares and institutions hold larger chunk of about 69.28% of that.
The stock has a current market capitalization of $5.19B and its 3Y-monthly beta is at 1.78. It has posted earnings per share of -$4.52 in the same period. It has Quick Ratio of 15.64 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRSP, volatility over the week remained 6.67% while standing at 5.82% over the month.
Analysts are in expectations that CRISPR Therapeutics AG (CRSP) stock would likely to be making an EPS of -1.44 in the current quarter, while forecast for next quarter EPS is -1.3 and it is -4.48 for next year. For the current quarter EPS, analysts have given the company a lowest target -2.27 which is -0.93 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.49 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -25.48% while it is estimated to increase by 18.02% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on February 14, 2025 offering an Outperform rating for the stock and assigned a target price range of between $60 and $99 to it. Coverage by TD Cowen stated CRISPR Therapeutics AG (CRSP) stock as a Hold in their note to investors on February 12, 2025, suggesting a price target of $35 for the stock. On February 03, 2025, H.C. Wainwright Initiated their recommendations, while on August 06, 2024, Needham Reiterated their ratings for the stock with a price target of $84. Stock get a Buy rating from Rodman & Renshaw on August 02, 2024.
